FTSE 250 (MCX)

LONDON (ShareCast) - (Sharecast News) - Shares in Oxford Biomedica tanked by a quarter on Friday after the cell and gene therapy manufacturer slashed its full year revenue and margins forecast citing short‑term client ordering delays, programme deferrals and operational delays at its North Carolina facility.


The company now expects 2026 revenue of £180m-200m compared with prior guidance of £220-240m.

Full-year EBITDA margin is expected to be mid-single-digit percentage - excluding one off costs - and low-single-digit on a reported basis, compared with the 10% guidance provided in March, reflecting lower than expected revenues and therefore absorption of operating costs.

Reporting by Frank Prenesti for Sharecast.com